Clinical Trials on Myelodysplastic Syndrome

Total 34157 results

Celgene

Completed

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Myelodysplastic Syndromes

Japan
Helsinn Healthcare SA

Completed

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (MEI-005)

Myelodysplastic Syndrome | MDS

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Topotecan in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Anemia

China
European Working Group of MDS in Childhood

Unknown

Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

Germany, Austria, Switzerland, Czech Republic, Netherlands, Denmark, Belgium, Italy, Poland
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
M.D. Anderson Cancer Center
Cellectar Biosciences, Inc.

Withdrawn

NOV-002 in Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome
University of Leipzig
Curis, Inc.

Terminated

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS)

Myelodysplastic Syndromes | Anemia

Germany
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Myelodysplastic Syndromes

China, Japan
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
Astex Pharmaceuticals, Inc.

Completed

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome | MDS

United States, Canada
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

Myelodysplastic Syndrome | MDS

United States
Mikkael Sekeres MD
National Cancer Institute (NCI)

Completed

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Cedars-Sinai Medical Center
Abbott

Completed

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Alison Walker
Seagen Inc.

Terminated

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Anemia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
European Organisation for Research and Treatment...

Unknown

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Anemia

Belgium, Switzerland, Czech Republic, Portugal, Austria, Netherlands, Slovakia
University of Leipzig
Celgene Corporation

Recruiting

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions (LENNON)

Myelodysplastic Syndromes | Anemia

Germany
Groupe Francophone des Myelodysplasies
Celgene

Recruiting

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Myelodysplastic Syndromes | MDS

France
Novartis Pharmaceuticals

Completed

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Japan
Weill Medical College of Cornell University
Jazz Pharmaceuticals

Completed

CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Relapsed Adult Acute Myeloid | Myelodysplastic Syndromes, Previously Treated

United States
Maria Sklodowska-Curie National Research Institute...
KCRI

Not yet recruiting

Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes (CLARA)

Acute Myeloid Leukemia Myelodysplastic Syndromes

Poland
Hoffmann-La Roche

Terminated

A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes, Myelogenous Leukemia, Acute

United States, Canada, Germany
BeiGene

Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative Neoplasm

China, United States, Australia, Spain, Korea, Republic of, New Zealand, Germany
Li Junmin

Withdrawn

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

Myelodysplastic Syndromes | P53 Mutation

China
Rennes University Hospital
Ministry of Health, France

Terminated

Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome (EPO)

Myelodysplastic Syndromes | Anemia | Hemopathies

France
Celyad Oncology SA

Withdrawn

EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (EPITHINK)

Myelodysplastic Syndromes | AML, Adult
Brian Jonas
Pharmacyclics LLC.

Completed

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in Transformation

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
University of California, San Francisco
Novartis

Completed

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndrome

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Peking University People's Hospital

Recruiting

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

Myelodysplastic Syndromes | Myeloid Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT

Acute Leukemia | Myelodysplastic Syndrome

United States
Peking University People's Hospital

Recruiting

RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

Myelodysplastic Syndromes | Acute Leukemia

China
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Completed

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

AML | MDS

United States
University Hospital, Brest

Recruiting

Biocollection in MyeloDysplastic Syndrome (P-MDS) (P-MDS)

Myelodysplastic Syndromes | Chromosome Abnormality | Acute Myeloid Leukemia With Multilineage Dysplasia | Myelodysplastic Syndrome With Ring Sideroblasts | Myelodysplastic Anemia | Myelodysplastic Syndrome With Isolated Del(5Q)

France
Humanigen, Inc.

Suspended

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Myelodysplastic Syndrome (MDS) | Myelofibrosis (MF)

United States, Australia
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Vanderbilt-Ingram Cancer Center
Astex Pharmaceuticals, Inc.; Forma Therapeutics, Inc.

Withdrawn

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Memorial Sloan Kettering Cancer Center

Completed

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Myelodysplastic Syndromes (MDS) | Acute Myelogenous Leukemia (AML)

United States
Aprea Therapeutics

Completed

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia or Myelodysplastic Syndromes

United States
Washington University School of Medicine
Cephalon

Completed

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Myelodysplastic Syndromes and Leukemia, Myeloid, Acute

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States

Clinical Trials on Myelodysplastic Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations